OIS@AAO 2017 Videos

In addition to bringing us up to date on Aerie Pharmaceuticals’ progress, Thomas A. Mitro, president and COO, sheds some light on his path to…

Chuck Hess, vice president and general manager at Bausch + Lomb, updates us on the company’s growing Stellaris Elite and Vitesse platforms as well as…

Yari Mitchell, vice president of medical affairs and business strategy at AcuFocus, updates OIS.TV on the progress of the Kamra Inlay and the promise of…

Dave Van Meter, president and CEO of Ivantis, explains how the company’s Hydrus Microstent plans to grab a piece of the growing MIGS market. He…

Thomas Frinzi, worldwide president, surgical, Johnson & Johnson Vision, shares some impressive milestones for the company’s Symfony and Symfony Toric IOLs. He also discusses the…

Few can track the past 10 years of advances in glaucoma treatment as well as Andrew Iwach, MD, executive director of the Glaucoma Center of…

Dan Myers, CEO of Alimera Sciences, says company growth is moving the firm into cash-positive territory in 2018. What challenges did he have to conquer…

Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing…

Joe Boorady, OD, president & CEO of TearScience, details the rollout of the company’s dry eye suite of tools now that it’s part of Johnson…

Tom Gadek, president and CEO of dry eye start-up TearSolutions, explains how his “religious vision quest” at SARcode Bioscience, the entity that developed the drug…

Iconic Therapeutics is looking to take a significant step in ophthalmology in 2018, William Greene, MD, CEO, said during the Company Showcase 3 session at…

Jonathan Norris, managing director at Silicon Valley Bank, points to increased fund-raising by healthcare-focused venture capital firms and a surge by strategic investors in Series…